RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
暂无分享，去创建一个
Weihu Wang | K. Zhao | R. Yu | Jiancheng Li | Tao Li | Wenqing Wang | Haishan Wu | Yidi Wang | W. Shen | Weihu Wang | Liyun Li | L. Liang | Wen-yan Yu | Wei Huang | Z. Xiao | Ta-shan Ai | C. Wei